The use of beta-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
Por:
Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P and Palazon J
Publicada:
1 oct 2016
Resumen:
IntroductionPatients with cirrhosis by hepatitis C virus infection
treated with -blockers (BB) have been shown to have a reduced incidence
of hepatocellular carcinoma (HCC). Also, an association between
propranolol therapy and lower incidence of other tumors has been
described.AimTo analyze the incidence of HCC according to BB treatment
in cirrhosis of any cause.Patients and methodsCirrhotic patients
included in the program for early detection of HCC were followed.
Patients' data were prospectively registered, including transplantation
and death. Patients were classified as chronically taken or not BB and
the proportions of patients who remained free of tumor from the
diagnosis of cirrhosis until the end of follow-up were compared using
Kaplan-Meier analysis and the Breslow test.ResultsA total of 173
patients (73 treated and 100 untreated BB) were followed. The median
duration of follow-up was 11 years. There were no differences between
both groups in the overall survival, number of deaths, or liver
transplant.Overall, 28 patients developed HCC during the follow-up, 20
patients who were untreated and eight patients treated with BB. The
cumulative proportion of cases of HCC between untreated and treated with
BB from the diagnosis of cirrhosis was statistically significant (6 vs.
3%, at 5 years; 19 vs. 6% at 10 years; 24 vs. 16% at 15 years; P=0.048).
Multivariate analyses showed BB intake as the only significant variable
associated with the development of HCC.ConclusionCirrhotic patients
treated with BB have a lower cumulative probability of developing HCC
during the 10 years after the diagnosis of cirrhosis.
Filiaciones:
Herrera I:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Dept Gastroenterol, Liver Unit, C Pintor Baeza S-N, Alicante 03010, Spain
Pascual S:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Dept Gastroenterol, Liver Unit, C Pintor Baeza S-N, Alicante 03010, Spain
Zapater P:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Clin Pharmacol Unit, Alicante, Spain
Univ Miguel Hernandez, Alicante, Spain
Carnicer F:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Dept Gastroenterol, Liver Unit, C Pintor Baeza S-N, Alicante 03010, Spain
Bellot P:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Dept Gastroenterol, Liver Unit, C Pintor Baeza S-N, Alicante 03010, Spain
Palazon J:
Hosp Gen Univ Alicante, CIBEREHD, Alicante, Spain
Hosp Gen Univ Alicante, Dept Gastroenterol, Liver Unit, C Pintor Baeza S-N, Alicante 03010, Spain
Univ Miguel Hernandez, Alicante, Spain
|